Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 557
- Registration Number
- NCT03867201
- Locations
- 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam
A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT03851705
- Locations
- 🇷🇺
(50007-001) Research Institute of Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
🇷🇸(50381-001) Clinical Center of Serbia, Belgrad, Serbia
🇹🇷(50090-001) Ege Universitesi, İzmir, Turkey
Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Combination Product: Docetaxel / CapecitabineCombination Product: Capecitabine / VinorelbineCombination Product: Paclitaxel / Gemcitabine
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 223
- Registration Number
- NCT03839823
- Locations
- 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT03832114
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
- Conditions
- Migraine
- Interventions
- Biological: ErenumabBiological: Erenumab matching placebo
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 777
- Registration Number
- NCT03828539
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Placebo to LYS006Drug: Placebo to CFZ533Drug: LOU064 25mgDrug: LOU064 100mgDrug: Placebo to VAY736Drug: Placebo to LOU064
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT03827798
- Locations
- 🇺🇸
Olympian Clinical Research ., Clearwater, Florida, United States
🇺🇸Park Avenue Dermatology, PA, Orange Park, Florida, United States
🇺🇸University of South Florida, Tampa, Florida, United States
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT03822468
- Locations
- 🇺🇸
Southern Cancer Center PC, Mobile, Alabama, United States
🇺🇸Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸Nebraska Cancer Specialists, Omaha, Nebraska, United States
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
- Conditions
- Sickle Cell Disease (SCD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 259
- Registration Number
- NCT03814746
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Levine Cancer Insitute Carolinas Healthcare System, Charlotte, North Carolina, United States
Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
- Conditions
- Heterozygous Familial HypercholesterolemiaASCVDElevated CholesterolHomozygous Familial Hypercholesterolemia
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3275
- Registration Number
- NCT03814187
- Locations
- 🇺🇸
Research Site 10001-014, Columbus, Ohio, United States
🇺🇸Research Site 10001-088, Houston, Texas, United States
🇺🇸Research Site 10001-091, Houston, Texas, United States
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT03810183
- Locations
- 🇬🇧
Novartis Investigative Site, Bradford, West Yorkshire, United Kingdom